Meeting
2024 ASCO Annual Meeting
PAS-004: A novel macrocyclic MEK inhibitor to inhibit cancer cell growth in vitro and tumor growth in mouse xenograft studies.
Authors
Graeme Currie
Pasithea Therapeutics Corp., South San Francisco, CA
Graeme Currie , Michael Leviten , Lisa Ryner , Uday Khire , Mathew Lazarus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3126)
DOI
10.1200/JCO.2024.42.16_suppl.3126
Abstract #
3126
Poster Bd #
271
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
MAPK pathway alterations as a targetable vulnerability in bladder cancer.
First Author: Vincent D'Andrea
First Author: Nuala McCabe
Poster
2017 ASCO Annual Meeting
Development of a pan-cancer 15 gene expression signature to detect a subgroup driven by EMT/MAPK signalling.
First Author: Nuala McCabe
Poster
2023 ASCO Annual Meeting
A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1.
First Author: Xiaojie Hu